14. LIFE BELOW WATER

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Reduces Holdings in Zoetis Inc. (NYSE:ZTS) – Defense World

Written by Amanda

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH trimmed its stake in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 40.5% during the first quarter, HoldingsChannel.com reports. The firm owned 1,383 shares of the company’s stock after selling 942 shares during the quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Zoetis were worth $264,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Horizon Investments LLC raised its stake in shares of Zoetis by 5.5% during the 4th quarter. Horizon Investments LLC now owns 9,113 shares of the company’s stock valued at $2,220,000 after purchasing an additional 477 shares during the period. Garrett Investment Advisors LLC bought a new stake in shares of Zoetis during the 4th quarter valued at $433,000. Mn Services Vermogensbeheer B.V. raised its stake in shares of Zoetis by 1.9% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 362,603 shares of the company’s stock valued at $88,486,000 after purchasing an additional 6,800 shares during the period. Freedom Day Solutions LLC raised its stake in shares of Zoetis by 0.9% during the 4th quarter. Freedom Day Solutions LLC now owns 10,258 shares of the company’s stock valued at $2,503,000 after purchasing an additional 92 shares during the period. Finally, Ensign Peak Advisors Inc raised its stake in shares of Zoetis by 13.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 278,020 shares of the company’s stock valued at $67,845,000 after purchasing an additional 33,950 shares during the period. Institutional investors own 90.73% of the company’s stock.

ZTS stock opened at $174.61 on Friday. The company has a market cap of $82.18 billion, a P/E ratio of 40.05, a price-to-earnings-growth ratio of 2.76 and a beta of 0.77. Zoetis Inc. has a 1 year low of $154.18 and a 1 year high of $249.27. The company has a debt-to-equity ratio of 1.12, a current ratio of 2.25 and a quick ratio of 1.58. The stock’s fifty day moving average price is $168.99 and its 200-day moving average price is $192.21.

Zoetis (NYSE:ZTSGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.22 by $0.10. Zoetis had a return on equity of 49.62% and a net margin of 26.27%. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same period in the previous year, the business earned $1.26 earnings per share. The business’s revenue was up 6.9% on a year-over-year basis. As a group, analysts expect that Zoetis Inc. will post 5.05 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Thursday, July 21st will be issued a $0.325 dividend. The ex-dividend date is Wednesday, July 20th. This represents a $1.30 annualized dividend and a dividend yield of 0.74%. Zoetis’s dividend payout ratio (DPR) is 29.82%.

A number of research firms recently issued reports on ZTS. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. The Goldman Sachs Group decreased their target price on Zoetis from $237.00 to $208.00 and set a “buy” rating on the stock in a research note on Thursday, May 19th. Citigroup reduced their price objective on Zoetis from $232.00 to $208.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 9th. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $275.00 to $225.00 in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Moderate Buy” and a consensus price target of $229.75.

In other Zoetis news, Director Willie M. Reed sold 1,855 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $162.31, for a total transaction of $301,085.05. Following the completion of the transaction, the director now owns 6,782 shares in the company, valued at $1,100,786.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roxanne Lagano sold 2,167 shares of the business’s stock in a transaction that occurred on Tuesday, April 26th. The shares were sold at an average price of $178.96, for a total value of $387,806.32. Following the completion of the sale, the executive vice president now owns 23,687 shares of the company’s stock, valued at approximately $4,239,025.52. The disclosure for this sale can be found here. Insiders own 0.12% of the company’s stock.

Zoetis Profile (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai